gliclazide has been researched along with Peripheral Arterial Diseases in 1 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We analyzed 10,624 patients with type 2 diabetes free from baseline major PAD in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) clinical trial." | 2.82 | Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. ( Chalmers, J; Harrap, S; Hirakawa, Y; Lisheng, L; Mancia, G; Marre, M; Mohammedi, K; Neal, B; Rodgers, A; Williams, B; Woodward, M; Zoungas, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mohammedi, K | 1 |
| Woodward, M | 1 |
| Hirakawa, Y | 1 |
| Zoungas, S | 1 |
| Williams, B | 1 |
| Lisheng, L | 1 |
| Rodgers, A | 1 |
| Mancia, G | 1 |
| Neal, B | 1 |
| Harrap, S | 1 |
| Marre, M | 1 |
| Chalmers, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925] | Phase 3 | 11,140 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for gliclazide and Peripheral Arterial Diseases
| Article | Year |
|---|---|
Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Endpoint Determination; Female; F | 2016 |